Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK and Safety of CNTO 3157 in Healthy Japanese and Caucasian Men
NCT02008279Phase 1Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Dec 2013
- Primary completion
- Aug 2014
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of CNTO3157 in asthma (7 arms), sponsored by Janssen Pharmaceutical. Primary endpoints: Frequency of adverse events, Serum concentrations of CNTO 3157 in Caucasian and Japanese participants following single subcutaneous doses and 1 more. Started Dec 2013; status: completed.
02
Drugs
CNTO3157
03
Conditions
asthma
Beyond the preview
Go deeper on NCT02008279.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02008279.